Patents by Inventor Chan Loi Yong

Chan Loi Yong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosage regimens for HCV combination therapy
    Patent number: 8822496
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carla Haefner, Gerhard Steinmann, Jerry O. Stern, Chan-Loi Yong
  • DOSAGE REGIMENS FOR HCV COMBINATION THERAPY
    Publication number: 20110268700
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
    Type: Application
    Filed: October 27, 2010
    Publication date: November 3, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Carla HAEFNER, Gerhard STEINMANN, Jerry O. STERN, Chan-Loi YONG
  • Method for administering BIRB 796 BS
    Publication number: 20030118575
    Abstract: Disclosed are methods of administering BIRB 796 BS, a p38 MAPK inhibitor, at particular dosages.
    Type: Application
    Filed: December 6, 2002
    Publication date: June 26, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Peter M. Grob, Jeffrey B. Madwed, Christopher Pargellis, Chan Loi Yong